American Journal of Psychiatry

The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical ...

https://doi.org/10.1176/appi.ajp.20240738

pdf

abstract

full text

CME

SAVE ARTICLE

Articles

High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study

Publication date: 12 September 2024

Pages879–892

Objective: The authors used longitudinal biobank data with up to 25 years of follow-up on over 2,600 clozapine users to derive reliable estimates of the real-world burden of clozapine adverse drug events (ADEs). Methods: A total of 2,659 participants in the ...

https://doi.org/10.1176/appi.ajp.20230744

CMEAudio

Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder

Publication date: 12 September 2024

Pages893–900

Objective: Antipsychotic effectiveness in preventing relapse declines around menopausal age in women with schizophrenia or schizoaffective disorder (SSD). It is not known whether systemic menopausal hormone therapy (MHT) can help to prevent psychosis ...

https://doi.org/10.1176/appi.ajp.20230850

VideoClinical Guidance

Risk of Incident Psychosis and Mania With Prescription Amphetamines

Publication date: 12 September 2024

Pages901–909

Objective: Amphetamine prescribing has increased in the United States in recent years. Previous research identified an increased risk of incident psychosis with prescription amphetamines. The purpose of this study was to examine the impact of dose levels ...

https://doi.org/10.1176/appi.ajp.20230329

Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders

Publication date: 01 October 2024

Pages910–919

Objective: Conceptual similarities between depressive and negative symptoms complicate biomarker and intervention development. This study employed a data-driven approach to delineate the neural circuitry underlying depressive and negative symptoms in ...

https://doi.org/10.1176/appi.ajp.20230655

Cell Type–Specific Profiles and Developmental Trajectories of Transcriptomes in Primate Prefrontal Layer 3 Pyramidal Neurons: Implications for Schizophrenia

Publication date: 01 October 2024

Pages920–934

Objective: In schizophrenia, impaired working memory is associated with transcriptome alterations in layer 3 pyramidal neurons (L3PNs) in the dorsolateral prefrontal cortex (DLPFC). Distinct subtypes of L3PNs that send axonal projections to the DLPFC in ...

https://doi.org/10.1176/appi.ajp.20230541